{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:55:09Z","timestamp":1769748909810,"version":"3.49.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.tcm.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T09:21:53Z","timestamp":1540113713000},"page":"353-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?"],"prefix":"10.1016","volume":"29","author":[{"given":"Andrea","family":"Corsonello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Lattanzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2018.10.008_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.tcm.2018.10.008_bib0002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12916-017-0804-x","article-title":"When is proton pump inhibitor use appropriate?","volume":"15","author":"Yadlapati","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0003","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.tcm.2018.10.008_bib0004","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/S0002-9270(00)02052-9","article-title":"Overuse of acid-suppressive therapy in hospitalized patients","volume":"95","author":"Nardino","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0005","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2003.01600.x","article-title":"Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey","volume":"17","author":"Parente","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0006","first-page":"325","article-title":"Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study","volume":"29","author":"Gullotta","year":"1997","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0007","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12603-015-0642-5","article-title":"Inappropriate use of proton pump inhibitors in elderly patients discharged from acute care hospitals","volume":"20","author":"Schepisi","year":"2016","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.tcm.2018.10.008_bib0008","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2174\/1389200219666171207125351","article-title":"Adverse events of proton pump inhibitors: potential mechanisms","volume":"19","author":"Corsonello","year":"2018","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.tcm.2018.10.008_bib0009","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","article-title":"Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine","volume":"128","author":"Ghebremariam","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.10.008_bib0010","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1038\/s41598-017-03069-1","article-title":"Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance","volume":"7","author":"Tommasi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tcm.2018.10.008_bib0011","article-title":"Different transcriptional profiling between senescent and non-senescent human coronary artery endothelial cells (HCAECs) by Omeprazole and Lansoprazole treatment","author":"Costarelli","year":"2016","journal-title":"Biogerontology"},{"key":"10.1016\/j.tcm.2018.10.008_bib0012","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1161\/CIRCRESAHA.116.308807","article-title":"Proton pump inhibitors accelerate endothelial senescence","volume":"118","author":"Yepuri","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.tcm.2018.10.008_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.106.666008","article-title":"Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms","volume":"116","author":"Schillinger","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.10.008_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20120045","article-title":"Drug-induced alterations in Mg2+ homoeostasis","volume":"123","author":"Lameris","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.tcm.2018.10.008_bib0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/nep.12226","article-title":"Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?","volume":"19","author":"Berney-Meyer","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.tcm.2018.10.008_bib0016","first-page":"749","article-title":"Slow, spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets: isolation and structural characterization of the toxic antioxidants 3H-benzimidazole-2-thiones","volume":"68","author":"Rajab","year":"2013","journal-title":"Pharmazie"},{"key":"10.1016\/j.tcm.2018.10.008_bib0017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MNH.0000000000000406","article-title":"The association of proton pump inhibitors and chronic kidney disease: cause or confounding?","volume":"27","author":"Li","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.tcm.2018.10.008_bib0018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ekir.2017.01.005","article-title":"Proton pump inhibitors and kidney disease-GI upset for the nephrologist?","volume":"2","author":"Toth-Manikowski","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.tcm.2018.10.008_bib0019","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2016.11.023","article-title":"Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency","volume":"152","author":"Lam","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tcm.2018.10.008_bib0020","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2018.10.008_bib0021","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cll.2014.08.008","article-title":"The impact of proton pump inhibitors on the human gastrointestinal microbiome","volume":"34","author":"Freedberg","year":"2014","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0022","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1023\/A:1026604203237","article-title":"Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells","volume":"44","author":"Ohara","year":"1999","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2018.10.008_bib0023","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2036.2000.014s1074.x","article-title":"A new mechanism for anti-inflammatory actions of proton pump inhibitors\u2013inhibitory effects on neutrophil-endothelial cell interactions","volume":"14","author":"Yoshida","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0024","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/00003246-200205000-00026","article-title":"Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity","volume":"30","author":"Zedtwitz-Liebenstein","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/08923970009016425","article-title":"Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro","volume":"22","author":"Agastya","year":"2000","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0026","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/tx5003782","article-title":"Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study","volume":"28","author":"Wu","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2710.2008.00907.x","article-title":"A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors","volume":"33","author":"Namazi","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0028","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12967-015-0614-x","article-title":"Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis","volume":"13","author":"Ghebremariam","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cbi.2017.04.010","article-title":"Lansoprazole halts contrast induced nephropathy through activation of Nrf2 pathway in rats","volume":"270","author":"Khaleel","year":"2017","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.tcm.2018.10.008_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bone.2013.08.013","article-title":"Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data","volume":"57","author":"Abrahamsen","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.tcm.2018.10.008_bib0031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01352010","article-title":"Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans","volume":"53","author":"Mizunashi","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.tcm.2018.10.008_bib0032","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0021-9673(01)01225-0","article-title":"Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography","volume":"949","author":"Cheng","year":"2002","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.tcm.2018.10.008_bib0033","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2710.2009.01100.x","article-title":"Proton pump inhibitors: predisposers to Alzheimer disease?","volume":"35","author":"Fallahzadeh","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0034","doi-asserted-by":"crossref","first-page":"e58837","DOI":"10.1371\/journal.pone.0058837","article-title":"The proton-pump inhibitor lansoprazole enhances amyloid beta production","volume":"8","author":"Badiola","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2018.10.008_bib0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.tcm.2018.10.008_bib0036","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00266355","article-title":"Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects","volume":"42","author":"Soons","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0037","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2018.10.008_bib0038","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00059-014-4188-9","article-title":"Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban","volume":"40","author":"Stollberger","year":"2015","journal-title":"Herz"},{"key":"10.1016\/j.tcm.2018.10.008_bib0039","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1056\/NEJMsb042458","article-title":"Potential pitfalls of disease-specific guidelines for patients with multiple conditions","volume":"351","author":"Tinetti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making - beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0041","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/jgs.12826","article-title":"Proton pump inhibitors and functional decline in older adults discharged from acute care hospitals","volume":"62","author":"Corsonello","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0042","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamainternmed.2013.2851","article-title":"Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals","volume":"173","author":"Maggio","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"488","key":"10.1016\/j.tcm.2018.10.008_bib0043","first-page":"e9","article-title":"Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland","volume":"13","author":"Teramura-Gronblad","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.tcm.2018.10.008_bib0045","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijcard.2012.03.085","article-title":"No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis","volume":"167","author":"Kwok","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0046","unstructured":"(https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm190784.htm)"},{"key":"10.1016\/j.tcm.2018.10.008_bib0047","first-page":"5","author":"Jackson","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0048","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/STROKEAHA.117.019166","article-title":"Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and meta-analysis","volume":"49","author":"Malhotra","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2018.10.008_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000248","article-title":"Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis","volume":"2","author":"Cardoso","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.tcm.2018.10.008_bib0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","article-title":"Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study","volume":"153","author":"Charlot","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124653","article-title":"Proton pump inhibitor usage and the risk of myocardial infarction in the general population","volume":"10","author":"Shah","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2018.10.008_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169826","article-title":"Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease","volume":"12","author":"Pello Lazaro","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2018.10.008_bib0053","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2036.2011.04890.x","article-title":"Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation","volume":"35","author":"Schmidt","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0054","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000637","article-title":"Efficacy and Safety of Proton Pump Inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials","author":"Dahal","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5414\/CNP68065","article-title":"Proton pump inhibitors and the kidney: critical review","volume":"68","author":"Brewster","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0056","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ki.2014.294","article-title":"Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly","volume":"87","author":"Muriithi","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.tcm.2018.10.008_bib0057","article-title":"The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis","author":"Nochaiwong","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.tcm.2018.10.008_bib0058","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.tcm.2018.10.008_bib0059","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton pump inhibitors and risk of incident CKD and progression to ESRD","volume":"27","author":"Xie","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0060","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tcm.2018.10.008_bib0061","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","article-title":"Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury","volume":"91","author":"Xie","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.tcm.2018.10.008_bib0062","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s10620-017-4725-5","article-title":"Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis","volume":"62","author":"Wijarnpreecha","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.tcm.2018.10.008_bib0063","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile Infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0064","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1017\/ice.2016.194","article-title":"Assessing the risk of hospital-acquired clostridium difficile infection with proton pump inhibitor use: a meta-analysis","volume":"37","author":"Arriola","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0065","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.mayocp.2011.12.021","article-title":"Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study","volume":"87","author":"Khanna","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0066","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ajg.2016.343","article-title":"Proton pump inhibitors do not increase risk for clostridium difficile infection in the intensive care unit","volume":"111","author":"Faleck","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0067","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ajg.2013.351","article-title":"Risk factors of community-acquired enteric infection","volume":"109","author":"Fujita","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0068","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.tcm.2018.10.008_bib0069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128004","article-title":"Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis","volume":"10","author":"Lambert","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2018.10.008_bib0070","first-page":"355","article-title":"Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study","author":"Othman","year":"2016","journal-title":"Bmj-Brit Med J"},{"key":"10.1016\/j.tcm.2018.10.008_bib0071","doi-asserted-by":"crossref","first-page":"i6041","DOI":"10.1136\/bmj.i6041","article-title":"Proton pump inhibitors and community acquired pneumonia","volume":"355","author":"Filion","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.tcm.2018.10.008_bib0072","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn","year":"2015","journal-title":"Ren Fail"},{"key":"10.1016\/j.tcm.2018.10.008_bib0073","unstructured":"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm245011.htm."},{"key":"10.1016\/j.tcm.2018.10.008_bib0074","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/j.ajkd.2015.05.012","article-title":"Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study","volume":"66","author":"Kieboom","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.tcm.2018.10.008_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/jgs.13212","article-title":"Proton pump inhibitors and hypomagnesemia in polymorbid elderly adults","volume":"63","author":"Pastorino","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0076","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2012.05201.x","article-title":"Systematic review: hypomagnesaemia induced by proton pump inhibition","volume":"36","author":"Hess","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0077","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.13194","article-title":"Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies","volume":"41","author":"Attwood","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tcm.2018.10.008_bib0078","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3177\/jnsv.62.330","article-title":"Effect of long-term proton pump inhibitor therapy on nutritional status in elderly hospitalized patients","volume":"62","author":"Nakamichi","year":"2016","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"10.1016\/j.tcm.2018.10.008_bib0079","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5603\/KP.a2015.0197","article-title":"Connections between nutritional status and proton pump inhibitor therapy in patients scheduled for cardiovascular rehabilitation after treatment for ischaemic and valvular heart disease","volume":"74","author":"Boban","year":"2016","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0080","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.3390\/nu7105416","article-title":"Association of Proton Pump Inhibitor (PPI) use with energy intake, physical activity, and weight gain","volume":"7","author":"Czwornog","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.tcm.2018.10.008_bib0081","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2018.10.008_bib0082","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","article-title":"The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study","volume":"24","author":"Fraser","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tcm.2018.10.008_bib0083","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ajg.2016.481","article-title":"Long-term proton pump inhibitor use is not associated with changes in bone strength and structure","volume":"112","author":"Targownik","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0084","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tcm.2018.10.008_bib0085","series-title":"Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors","year":"2010"},{"key":"10.1016\/j.tcm.2018.10.008_bib0086","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/s41598-017-05552-1","article-title":"Proton pump inhibitors and the risk for fracture at specific sites: data mining of the fda adverse event reporting system","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tcm.2018.10.008_bib0087","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00406-014-0554-0","article-title":"Risk of dementia in elderly patients with the use of proton pump inhibitors","volume":"265","author":"Haenisch","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.tcm.2018.10.008_bib0088","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0089","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171006","article-title":"Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan","volume":"12","author":"Tai","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.tcm.2018.10.008_bib0090","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/jgs.14956","article-title":"Proton pump inhibitors and risk of mild cognitive impairment and dementia","volume":"65","author":"Goldstein","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0091","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/jgh.13750","article-title":"Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review","volume":"32","author":"Batchelor","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0092","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/ajg.2018.29","article-title":"Discontinuing long-term PPI therapy: why, with whom, and how?","volume":"113","author":"Targownik","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tcm.2018.10.008_bib0093","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/SMJ.0b013e31828db01f","article-title":"Four-year trends of inappropriate proton pump inhibitor use after hospital discharge","volume":"106","author":"Leri","year":"2013","journal-title":"South Med J"},{"key":"10.1016\/j.tcm.2018.10.008_bib0094","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.4135","article-title":"Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study","volume":"26","author":"Wallerstedt","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.tcm.2018.10.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.14528","article-title":"Characterizing potentially inappropriate prescribing of proton pump inhibitors in older people in primary care in ireland from 1997 to 2012","volume":"64","author":"Moriarty","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0096","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1532-5415.2010.02819.x","article-title":"Daily medication use in nursing home residents with advanced dementia","volume":"58","author":"Tjia","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tcm.2018.10.008_bib0097","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173818302433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173818302433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:59:26Z","timestamp":1760936366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173818302433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1050173818302433"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2018.10.008","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}